CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CURIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.38−0.03 (-6.26%)
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$30.4184 (−98.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
CURIS INC saw revenue fall 62.2% to $4.31M over the twelve months to Jun 30, 2026.
Revenue
$4.31M
-62.2% vs. a year earlier
Operating income
-$8.76M
TTM Q2 2026
EPS, diluted
-$11.60
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $815.06K
- P/E ratio
- –
- Price to sales
- 0.19
- Price to book
- 0.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.31M
- Net income
- -$21.15M
- EPS, diluted
- -$11.60
- Book value per share
- $2.20
- Diluted shares
- 2M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.31M-62.2% YoY
Operating income
-$8.76M
Net income
-$21.15M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months